Literature DB >> 9082586

[The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].

H Sauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9082586     DOI： 10.1007/bf03039195

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  7 in total

1.  Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.

Authors:  K Hellmann
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

2.  Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.

Authors:  S E Lipshultz
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

Review 3.  Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.

Authors:  C F Seifert; M E Nesser; D F Thompson
Journal:  Ann Pharmacother       Date:  1994-09       Impact factor: 3.154

4.  A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.

Authors:  K Kolaric; V Bradamante; J Cervek; A Cieslinska; E Cisarz-Filipcak; L E Denisov; D Donat; K Drosik; M Gershanovic; P Hudziec
Journal:  Oncology       Date:  1995 May-Jun       Impact factor: 2.935

5.  Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.

Authors:  R L Basser; M M Sobol; G Duggan; J Cebon; M A Rosenthal; G Mihaly; M D Green
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

6.  Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.

Authors:  S Jelić; S Radulović; Z Nesković-Konstantinović; M Kreacić; Z Ristović; S Bosnjak; N Milanović; L Vuletić
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

7.  Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

Authors:  L H Wexler; M P Andrich; D Venzon; S L Berg; L Weaver-McClure; C C Chen; V Dilsizian; N Avila; P Jarosinski; F M Balis; D G Poplack; M E Horowitz
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.